It would appear Johnson & Johnson was also circling US-listed Global Blood Therapeutics, which two weeks ago agreed a deal to sell itself to pharmaceutical giant Pfizer for $5.4 billion.
Well, that's according to arch rivals at Bloomberg. Below is a link to the Bloomie story that came out overnight:..
The US deal announcements are now arriving thick and fast.
Aside from the takeovers mentioned in this morning's note, Pfizer has announced it is buying Global Blood Therapeutics for $5.4 billion (confirming the Bloomberg and Wall Street Journal scoops from last week). Below is the link to the deal report from the WSJ:..
Global Blood Therapeutics, a US-listed biopharmaceutical company, is a business that has been on Betaville's radar for quite a few years amid vague rumours.
Now, though, arch rivals at Bloomberg are reporting that the company - which makes drugs for sickle cell disease - is working with advisers amid takeover interest from larger rivals...